The Office of Diversity and Inclusion encourages and supports the teaching, learning, and working environments of students, faculty, and staff in order to have a positive effect on the health experiences of diverse communities. Consequently, the Office of Diversity and Inclusion will support and promote all research efforts that recognize and value diversity and inclusion as a tool to reduce health inequities and improve the health of historically marginalized and underserved populations.
Diversity and equity are essential to the development of future leaders in healthcare and research; they enrich intellectual development, academic discourse, patient care, and research. That is why our office commits to developing innovative programs that educate, recruit, and retain a diverse, multicultural community of faculty, students, staff, and trainees.
The School has been committed to inclusion and diversity since our founding—both at the school and through our community outreach. Created by a merger of Boston University and the New England Female Medical College in 1873, we were the first coeducational medical school in the nation. Our alumni include the first black female physician and the first Native American physician. It’s more than just talk for us. Recruiting and retaining a heterogeneous student body and faculty are a priority. We firmly believe in diversity of culture, race, and gender—and also ideas, solutions, and perspectives as critical components of achieving excellence at Chobanian & Avedisian School of Medicine.
Register now! Virtual Event | Feb. 8 | 6-7:30 p.m. (EST)
A panel of accomplished alumnae will reflect on their own experiences as physicians, their time in medical school and how Dr. Crumpler's legacy impacts their work with patients, students and communities.
Physician and scientist Drew Weissman, who earned both an MD and a PhD at Boston University, and his research collaborator, Katalin Karikó, have won the 2023 Nobel Prize in Physiology or Medicine
It is not the quantity but the quality of LDL that contributes to disease
The nominators say, “Cheryl is the heart and soul of the department.”
The nominators say, “Dr. Subramanian embodies all aspects of an academic physician.”
Findings highlight promising targets for lung fibrosis treatments
A more thorough and specific understanding of how glycosylation affects disease may provide novel targets in diseases that currently lack effective treatment options
Congratulations to Professors Elijah Paintsil and Frederick Ruberg; Research Professor Yuriy Alekseyev; Associate Professors Matthew Nayor, Michelle Bovin, Andreea Bujor, Shuaiying Cui, Katherine Gergen Barnett and Karin Schon; and Clinical Associate Professors Linda Ng and Rachel Stark.
The Alzheimer’s Drug Discovery Foundation’s Goodes Prize supports researchers transforming the field by translating the biology of aging into new therapeutics and diagnostic tools.